BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
12 déc. 2023 09h15 HE
|
BioRestorative Therapies, Inc
--Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023 ...
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
15 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 ...
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
02 déc. 2021 09h15 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Nanocelle® Patent Granted in Usa
04 nov. 2021 09h35 HE
|
Medlab Clinical Ltd
Medlab receives Granted Patent Protection for NanoCelle® in the USA by US Patent & Trademark Office (USPTO) SYDNEY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX: MDC) is...
Citrine Global Subsidiary Files in the U.S. Patent & Trademark Office a Provisional Patent Application for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE USE OF CANNABIS & RELATED PRODUCTS”
02 nov. 2021 10h42 HE
|
Citrine Global, Corp.
Tel Aviv, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Citrine Global, Corp. (OTCQB: CTGL) is pleased to announce that its subsidiary, Cannovation Center Israel Ltd., has filed in the U.S. Patent &...
Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office
15 juil. 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 ...